Osocimab

Osocimab (BAY 1213790), an anti-FXIa antibody (Ki=2.4 nM; EC50=0.2 nM) . FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects[1].

Product Specifications

CAS Number

[2056878-75-0]

Product Name Alternative

BAY 1213790

UNSPSC

12352203

Target

Factor Xa

Type

Inhibitory Antibodies

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/osocimab.html

Purity

98.00

Solubility

10 mM in DMSO

Smiles

[Osocimab]

Molecular Weight

(145.5 kDa)

References & Citations

[1]Schaefer M, et al. Allosteric Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated Form of Coagulation Factor XI. J Mol Biol. 2019 Dec 6;431 (24) :4817-4833.